Aleksandra Franovic

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Smoking Cessation

Tyrosine Kinase

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)